Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder ...

PulseSight plans to submit a phase I clinical trial authorization (CTA) by the end the year, to be closely followed by a phase II proof-of-concept to demonstrate the efficacy and the safety of its ...

You can still live a full life with geographic atrophy (GA). Even though your vision may be different, GA doesn’t lead to total blindness. You can use your remaining vision and make certain ...

Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).

Astellas Pharma Inc. has withdrawn its marketing authorization application from the EMA for its avacincaptad pegol intravitreal solution for the treatment of geographic atrophy secondary to ...

In advanced stages, dry AMD progresses into geographic atrophy (GA), characterized by atrophy of the retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris, responsible for a ...

GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the ...